⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

Official Title: A Randomized, Phase III Comparison of Gemcitabine/Irinotecan Followed by IRESSA Versus Paclitaxel/Carboplatin/Etoposide Followed by IRESSA in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site

Study ID: NCT00193596

Study Description

Brief Summary: In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.

Detailed Description: Upon determination of eligibility, all patients will be randomly assigned to one of two treatment arms: * Paclitaxel + Carboplatin + Etoposide * Irinotecan + Gemcitabine Patients will be stratified by tumor location (liver/bone versus all others) and number of metastatic sites (one versus two or more). Patients with an objective response or stable disease after completion of chemotherapy will receive ZD1839 until disease progression. Patients who do not respond to chemotherapy may crossover to the other chemotherapy regimen and will receive ZD1839 if they have an objective response or stable disease. The study is not blinded so both the patient and the doctor will know which treatment has been assigned.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Northeast Alabama Regional Medical Center, Anniston, Alabama, United States

Clearview Cancer Institute, Huntsville, Alabama, United States

Southern Cancer Center, Sacred Heart Heath System Medical Oncology Group, Mobile, Alabama, United States

Northeast Arkansas Clinic, Jonesboro, Arkansas, United States

Tower Oncology, Beverly Hills, California, United States

Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States

Mercy Hospital Miami, Miami, Florida, United States

Florida Hospital Cancer Institute, Orlando, Florida, United States

Phoebe Cancer Center, Albany, Georgia, United States

Northeast Georgia Medical Center, Gainesville, Georgia, United States

Wellstar Cancer Research, Marietta, Georgia, United States

Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States

Graves-Gilbert Clinic, Bowling Green, Kentucky, United States

Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States

Terrebonne General Medical Center, Houma, Louisiana, United States

Mercy Hospital, Portland, Maine, United States

Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States

St. Joseph Mercy Oakland Hospital, Cancer Center, Pontiac, Michigan, United States

Jackson Oncology Associates, Jackson, Mississippi, United States

Montana Cancer Institute Foundation, Missoula, Montana, United States

Methodist Cancer Center, Omaha, Nebraska, United States

Aultman Hospital, Canton, Ohio, United States

Oncology Hematology Care, Cincinnati, Ohio, United States

Consultants in Medical Oncology and Hematology, Drexel Hill, Pennsylvania, United States

Reading Hospital Regional Cancer Center, West Reading, Pennsylvania, United States

Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States

Kingsport Hematology-Oncology, Kingsport, Tennessee, United States

Thompson Cancer Survival Center, Knoxville, Tennessee, United States

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

South Texas Oncology and Hematology, San Antonio, Texas, United States

Cancer Outreach Associates, Abingdon, Virginia, United States

Contact Details

Name: John D. Hainsworth, MD

Affiliation: SCRI Development Innovations, LLC

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: